Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.

Single dose escalation studies with inhaled POL6014, a potent novel selective reversible inhibitor of human neutrophil elastase, in healthy volunteers and subjects with cystic fibrosis.

Published

Barth, P., Bruijnzeel, P., Wach, A., Sellier Kessler, O., Hooftman, L., Zimmermann, J., Naue, N., Huber, B., Heimbeck, I., Kappeler, D., Timmer, W., Chevalier, E. (2019).

Journal of Cystic Fibrosis.
 

Read the publication

Back to overview